Cytokines News and Research

Latest Cytokines News and Research

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.

31 Dec 2014

Study finds that binge drinking can significantly disrupt immune system

Binge drinking in young, healthy adults significantly disrupts the immune system, according to a study led by a researcher now at Loyola University Chicago Stritch School of Medicine.

30 Dec 2014

CytoSorbents starts trading on The Nasdaq Capital Market

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO".

23 Dec 2014

Trophoblasts respond to inflammatory danger signals, find NTNU researchers

Trophoblasts, cells that form an outer layer around a fertilized egg and develop into the major part of the placenta, have now been shown to respond to inflammatory danger signals, researchers from Norwegian University of Science and Technology found in a recent study published in Journal of Reproductive Immunology December 2014.

18 Dec 2014

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.

9 Dec 2014

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells.

9 Dec 2014

Study reveals how elite Kenyan athletes succeed in long-distance races

The Journal of Applied Physiology has published an article by Jordan Santos-Concejero of the Faculty of Physical Activity and Sport Sciences of the University of the Basque Country, and entitled `Maintained cerebral oxygenation during maximal self-paced exercise in elite Kenyan runners'. This is a pioneering study in the world of the physiology of exercise, given that it describes for the first time that elite Kenyan athletes have greater brain oxygenation during periods of maximum physical effort, and which contributes to their success in long-distance races.

7 Dec 2014

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.

7 Dec 2014

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over recent years. Globally, there are approximately 750,000 new cases of liver cancer reported each year. Importantly, population-based studies show that HCC ranks as the third leading cause of cancer-related deaths worldwide.

4 Dec 2014

Researchers identify possible prognostic biomarker in triple-negative breast cancer

"Triple-negative" breast cancer (TNBC) occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER-/PR-/HER2-).

2 Dec 2014

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

The type 3 interferons - usually called the “lambda” interferons, or “IFNL” - are the most recently identified IFNs. We (myself and Sergei Kotenko) originally identified the receptor and then the three ligands (IFNL1,2,3; very recently a fourth, IFNL4, was discovered); the key paper was published in 2003.

18 Nov 2014

Chaetocin synergistic with TKIs against CML cells

Chaetocin, a mycotoxin that increases oxidative stress, can complement the activity of tyrosine kinase inhibitors in chronic myeloid leukaemia by overcoming innate resistance mediated by secreted bone marrow stromal cytokines and growth factors, researchers report.

14 Nov 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

Study suggests possible link between body fat and risk of immunotherapy toxicity

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found.

4 Nov 2014

Bio-Techne to acquire CyVek for $60M

Bio-Techne Corporation announced today that it has agreed to acquire CyVek, Inc. (CyVek) for $60 million in cash, plus a potential earn-out payment of up to $35 million based on CyVek revenue over the 30-month period following the closing and an additional potential earn-out payment based on CyVek revenue through 2020 in excess of $100 million.

4 Nov 2014

UC Davis researchers link increased body fat and lethal drug reactions in mice

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. The findings, published online today in The Journal of Experimental Medicine, suggest a possible link between body fat and the risk of toxicity from some types of immunotherapy.

3 Nov 2014

Study identifies new targets for developing novel treatment for alcohol dependence

Bacteria in the gastrointestinal tract fulfill many vital functions and are critical for digestion. Yet, these same bacteria can induce strong inflammatory responses by the immune system if they penetrate the gut and enter the bloodstream.

31 Oct 2014

Japanese mushroom extract shows promise in eradicating HPV

A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.

29 Oct 2014

Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

The classic description of game theory was described by the prisoner's dilemma, which is a situation in which two players have two options where the outcome depends on the simultaneous choice made by the other.

29 Oct 2014

Digoxin drug may be adaptable for ALS treatment, study suggests

Digoxin, a medication used in the treatment of heart failure, may be adaptable for the treatment of amyotrophic lateral sclerosis (ALS), a progressive, paralyzing disease, suggests new research at Washington University School of Medicine in St. Louis.

27 Oct 2014